The question of NIH research dollars going toward facilities and administrative costs underwent a second going-over this year in the U.S. House of Representatives, and Keith Yamamoto of the University of California-San Francisco (UCSF) told a congressional committee that a hard cap of 10 percent on these indirect costs would have "a very strong detrimental effect on capacity to start up new [life science] companies and keep them healthy."